Ruxolitinib
- PDF / 169,629 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 158 Views
1 S
Ruxolitinib discontinuation syndrome: case report A 70-year-old woman developed ruxolitinib discontinuation syndrome (RDS) during treatment with ruxolitinib for polycythaemia vera. The woman started receiving ruxolitinib [route and dosage not stated] for polycythaemia vera. However, she progressed to myelofibrosis. An unspecified PIM kinase inhibitor was added to her regimen, but during follow up, she was found to have an elevated WBC count, compatible with acute myeloid leukaemia. Therefore, ruxolitinib was withheld, and she was hospitalised for the treatment of hyper-leucocytosis. However, she developed tender massive splenomegaly, thrombocytopenia and worsening dyspnoea. An abdominal CT scan showed perisplenic haemorrhage and colitis. CT angiogram demonstrated diffuse inflammatory lung nodules. Laboratory investigations were negative for infection. Hence, RDS was considered and she started receiving prednisone. Ruxolitinib was resumed later, due to the development of excruciating abdominal pain secondary to rebound splenomegaly. Subsequently, the pain and respiratory distress improved significantly, confirming the diagnosis of RDS. The woman was eventually discharged on ruxolitinib and taper of prednisone. Shakir A, et al. Ruxolitinib discontinuation syndrome in a patient with myelofibrosis to acute myeloid leukemia transformation. American Journal of Respiratory and Critical Care Medicine 199: abstr. A 1479, No. 9, May 2019. Available from: URL: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1479 803447619 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
